GlaxoSmithKline taps law firm to probe China fiasco; Shire beats with 6% earnings hike;

@FiercePharma: FTC eyeing new patent deals for pay-for-delay action in wake of SCOTUS ruling. ICYMI yesterday | Follow @FiercePharma

@CarlyHFierce: Wednesday at Fierce, starring Neuron, Measles, Tuberculosis, MRSA and E. coli. Image | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) hired the British law firm Ropes & Gray to conduct an independent investigation of the root cause of alleged fraud among its senior executives in China. Report

> Shire ($SHPG) topped expectations with a 6% increase in second-quarter earnings, aided by strong sales of its Lialda colitis treatment and ADHD drugs Vyvanse and Intuniv. Report

> Traders who allegedly profited off of insider knowledge about a potential sale of Onyx Pharmaceuticals ($ONXX) have come forward, protesting their innocence. Report

> Finnish drugmaker Orion said it settled a patent fight with Mylan ($MYL) over Orion's Parkinson's drug Stalevo; the terms were undisclosed. Report | Release

> Iran's pharma market is growing, with drug spending projected to hit $4.14 billion by 2019, up from $3.51 billion last year. Report

> Slovenia's Krka posted a 6% increase in sales to 597 million euros, or $788 million. Report

> The human papillomavirus (HPV) that can cause cervical cancer has now been linked to esophageal cancer, in addition to throat and other cancers. Report

Medical Device News

@FierceMedDev: Boston Scientific's Q2 reflects both stagnation and promising growth. Article | Follow @FierceMedDev

@MarkHFierce: We are entering our last week for FMD F15 nominations. Get yours in now. Submission form | Follow @MarkHFierce

@DamianFierce: Roche posted only slight diagnostics growth in H1, as a diabetes slump weighed down testing sales. Story | Follow @DamianFierce

 @MichaelGFierce: From Novaliq secures CE mark for OTC drop to treat dry eye. Report | Follow @MichaelGFierce

> Abbott wins FDA nod for glucose monitor. More

> Blood Dx to predict sepsis-related death may be within reach. Item

> Abbott slashes 200 more jobs from CA stent operation. Report

Biotech News

@FierceBiotech: ICYMI: Sanofi returns to the crowdsourcing well for diabetes app. Article | Follow @FierceBiotech

@RyanMFierce: Stem cell pioneer's biotech startup raises $46M in IPO. Report | Follow @RyanMFierce

@EmilyMFierce: Inovio Pharma DNA cancer vaccine causes tumor death in animals. Article | Follow @EmilyMFierce

> AstraZeneca, Bristol resubmit NDA for diabetes therapy dapagliflozin. Report

> Johnson & Johnson, Vertex execs speak up for 'breakthrough' status in Washington. Article

> Teva, Lonza end biosimilars joint venture as the copycat crowd thins. News

> Industry Voices: mRNA-Based Therapies--Blueprints for Therapeutics. Feature

Pharma Manufacturing News

@EricPFierce: CMO Exela looks to get $1 million USDA loan to help expand plant, add jobs. Story | Follow @EricPFierce

> Fresenius Kabi Indian plant accused of manipulating data. More

> Lonza phasing out troubled Massachusetts biologics plant. Report

> FMC spends $345M for Epax omega-3 plants. Item

> FDA excoriates Wockhardt over missing records, standing urine. Story

> GSK looks to manufacturing to reduce vaccine costs. Article

Vaccines News

> Indian ethics journal pushes for ban on Crucell vaccine. Item

> Serum targets Merck, Sanofi stronghold with TB vax deal. More

> U.K. rejection of Bexsero hits Novartis vaccine unit. Report

> Lupin eyes vaccine growth after in-licensing Merck shot. News

> GSK planning joint venture to tap into Chinese vaccine demand. Article

> Study suggests GSK's Cervarix can prevent throat cancer. Story

And Finally... The current vaccines against whooping cough are only 53% to 64% effective in people older than 11, a BMJ study found. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.